Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ticarcillin sodium (Aerugipen hydrate) 主要用于抗革兰氏阴性菌, 也能用于研究嗜麦芽感染。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
10 mg | ¥ 273 | 待询 | ||
25 mg | ¥ 432 | 待询 | ||
50 mg | 特惠询价 | 待询 | ||
1 mL * 10 mM (in DMSO) | ¥ 160 | 待询 |
Ticarcillin sodium 的其他形式现货产品:
产品描述 | Ticarcillin sodium (Aerugipen hydrate) is a semisynthetic antibiotic with a broad spectrum of bactericidal activity against many gram-positive and gram-negative aerobic and anaerobic bacteria. |
体外活性 | MICs of Ticarcillin (64 mg/mL) for 90% of all beta-lactamase-positive strains are reduced to 2 mg/mL, with the addition of clavulanate. MICs of Ticarcillin for 90% of all beta-lactamase-negative strains are 4 mg/mL. 93.4% of the beta-lactamase-producing strains are susceptible to Ticarcillin at less than or equal to 64 mg/mL. [1] Ticarcillin/potassium clavulanate is light stable and resistant to inactivation by β-lactamase. Ticarcillin/potassium clavulanate is more economical than carbenicillin and cefotaxime to eliminate Agrobacterium tumefaciens in plant transformation. [2] |
体内活性 | The mean elimination half-life of Ticarcillin (120 mg/kg) in serum is 70.8 minutes in the control subjects and 53.1 minutes in the patients with cystic fibrosis. The total body clearance of Ticarcillin is significantly higher in cystic fibrosis patients (65.6 mL/min/m2 versus 46.2 mL/min/m2 in control subjects). The nonrenal clearance of ticarcillin is also significantly higher in patients with cystic fibrosis (24.8 mL/min/m2 versus 13.3 mL/min/m2 for the control group). [3] Ticarcillin/clavulanate (3.1 g, given iv every 4-6 hours) results in clinical success rate of 80.3% and clinical failure rate of 19.7% in the treatment of complicated skin and skin-structure infections. The overall rate of eradication is 83.7% in the Ticarcillin/clavulanate treatment group in the microbiologically evaluable population. [4] Ticarcillin/clavulanate results in cure rates of 79% at the time of final assessment for the treatment of intra-abdominal infections in pediatric and adult patients. [5] |
别名 | Ticarpen hydrate, Aerugipen hydrate, 替卡西林单钠盐单水合物, BRL 2288, AB 2288, Monapen |
分子量 | 430.41 |
分子式 | C15H16N2O6S2·2Na |
CAS No. | 29457-07-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ethanol: < 1 mg/mL (insoluble or slightly soluble)
DMSO: 80 mg/mL (185.9 mM)
H2O: 79 mg/mL (183.5 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO / H2O | 1 mM | 2.3234 mL | 11.6168 mL | 23.2337 mL | 58.0842 mL |
5 mM | 0.4647 mL | 2.3234 mL | 4.6467 mL | 11.6168 mL | |
10 mM | 0.2323 mL | 1.1617 mL | 2.3234 mL | 5.8084 mL | |
20 mM | 0.1162 mL | 0.5808 mL | 1.1617 mL | 2.9042 mL | |
50 mM | 0.0465 mL | 0.2323 mL | 0.4647 mL | 1.1617 mL | |
100 mM | 0.0232 mL | 0.1162 mL | 0.2323 mL | 0.5808 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Ticarcillin sodium 29457-07-6 Microbiology/Virology Others Antibacterial Antibiotic Ticarpen Hydrate Ticarpen hydrate Bacterial Gram-negative Inhibitor inhibit AB-2288 Aerugipen hydrate 替卡西林单钠盐单水合物 Ticarcillin BRL 2288 BRL-2288 AB 2288 AB2288 Aerugipen Hydrate BRL2288 Monapen inhibitor